Evidence map›Paper›PMID 36979661›Full record

ArticleBiomedicines2023

The Impact of YRNAs on HNSCC and HPV Infection.

Kacper Guglas, Tomasz Kolenda, Joanna Kozłowska-Masłoń, Patricia Severino, Anna Teresiak, Renata Bliźniak, Katarzyna Lamperska

Open access · goldFull text read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. lncRNABiomedicines · 2025
    Article
  4. Diagnostic Potential ofInternational journal of molecular sciences · 2024
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Kacper GuglasLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland.ORCID 0000-0002-2296-7808
Tomasz KolendaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland.
Joanna Kozłowska-MasłońLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland.ORCID 0000-0001-6914-4852
Patricia SeverinoAlbert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil.ORCID 0000-0002-6682-9343
Anna TeresiakLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland.
Renata BliźniakLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland.
Katarzyna LamperskaLaboratory of Cancer Genetics, Greater Poland Cancer Centre, Garbary Street 15, 61-866 Poznan, Poland.
Greater Poland Cancer Center · PLHospital Israelita Albert Einstein · BRMedical University of Warsaw · PL

Funding

Greater Poland Cancer Center 6/04/2021/PGN/WCO/002
6 · The paper itself

Abstract

HPV infection is one of the most important risk factors for head and neck squamous cell carcinoma among younger patients. YRNAs are short non-coding RNAs involved in DNA replication. YRNAs have been found to be dysregulated in many cancers, including head and neck squamous cell carcinoma (HNSCC). In this study, we investigated the role of YRNAs in HPV-positive HNSCC using publicly available gene expression datasets from HNSCC tissue, where expression patterns of YRNAs in HPV(+) and HPV(-) HNSCC samples significantly differed. Additionally, HNSCC cell lines were treated with YRNA1-overexpressing plasmid and RNA derived from these cell lines was used to perform a NGS analysis. Additionally, a deconvolution analysis was performed to determine YRNA1's impact on immune cells. YRNA expression levels varied according to cancer pathological and clinical stages, and correlated with more aggressive subtypes. YRNAs were mostly associated with more advanced cancer stages in the HPV(+) group, and YRNA3 and YRNA1 expression levels were found to be correlated with more advanced clinical stages despite HPV infection status, showing that they may function as potential biomarkers of more advanced stages of the disease. YRNA5 was associated with less-advanced cancer stages in the HPV(-) group. Overall survival and progression-free survival analyses showed opposite results between the HPV groups. The expression of YRNAs, especially YRNA1, correlated with a vast number of proteins and cellular processes associated with viral infections and immunologic responses to viruses. HNSCC-derived cell lines overexpressing YRNA1 were then used to determine the correlation of YRNA1 and the expression of genes associated with HPV infections. Taken together, our results highlight the potential of YRNAs as possible HNSCC biomarkers and new molecular targets.

Indexed as

biomarkerdeconvolutionHNSCCHPVNGSshort non-coding RNAYRNA

Identifiers

PMID36979661
PMCPMC10045647
OpenAlexW4321790172

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read55
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.